

Re: Your request made under the Freedom of Information Act 2000

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib
- Alectinib
- Atezolizumab monotherapy
- Atezolizumab in combination
- Bevacizumab
- Brigatinib
- Capmatenib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy
- Durvalumab
- Erlotinib
- Gefitinib
- Gemcitabine

Our Ref: 138/2022

JANUARY 2022

- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel
- Pembrolizumab monotherapy
- Pembrolizumab in combination
- Pemetrexed with Carboplatin/Cisplatin
- Tepotinib
- Vinorelbine with Cisplatin/Carboplatin
- Any other SACT
- Palliative care only